LP | Jotup

Taurus Private Markets Closes $211 Million Oversubscribed Private Equity Fund

Retrieved on:

Thursday, December 7, 2023

Entrepreneurship, LP, Partnership, Insurance, Market, Consultant, Financial services

MALVERN, Pa., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Taurus Private Markets, a Pennsylvania based private equity firm, today announced the final close of Taurus Private Markets Fund II, LP.

Key Points:

MALVERN, Pa., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Taurus Private Markets, a Pennsylvania based private equity firm, today announced the final close of Taurus Private Markets Fund II, LP.
“Raising capital for a private equity fund in the current market environment is a challenge.
Taurus Private Markets invests in value-oriented, lower middle market leveraged buyout and private credit partnerships with target fund sizes less than $1.25 billion.
It is our belief the lower middle market of private equity and private credit, along with early stage venture capital, continue to have the ability to generate compelling returns for investors,” said Kevin Campbell, Co-Founder and Managing General Partner of Taurus Private Markets.

Paycor Announces Offering of Common Stock by Selling Stockholder

Retrieved on:

Wednesday, December 6, 2023

Telephone, Partnership, Sale, Jefferies Group, Form, LP, Attention, Jefferies, HCM, Apax Partners, Form S-3, Prospectus, Madison Avenue, Security (finance)

CINCINNATI, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (HCM) software, today announced the commencement of an underwritten public offering of 5,000,000 shares of common stock on behalf of Pride Aggregator, LP.

Key Points:

CINCINNATI, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (HCM) software, today announced the commencement of an underwritten public offering of 5,000,000 shares of common stock on behalf of Pride Aggregator, LP.
The selling stockholder is controlled by investment funds advised by Apax Partners LLP.
The proposed offering of common stock will be made pursuant to the Company’s shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (“SEC”) and declared effective.
These forward-looking statements reflect Paycor’s current intentions, expectations or beliefs regarding the proposed common stock offering.

LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

Retrieved on:

Friday, December 1, 2023

Schedule, Patient, LP, Proposal

SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the “Proposal”) to acquire 100% of the equity of LianBio.

Key Points:

SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the “Proposal”) to acquire 100% of the equity of LianBio.
According to the Schedule 13D filed on November 30, 2023 with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital1 is currently approximately an 8.6% shareholder of LianBio.
The Proposal consists of $4.30 in cash per share plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs.
The Board is committed to acting in the best interests of all shareholders, consistent with its fiduciary duties.

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Retrieved on:

Wednesday, November 29, 2023

Ocean Biomedical, Form, LP, Bank statement, Cryptocurrency

As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q.

Key Points:

As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q.
In accordance with this interpretation, Ocean Biomedical has determined to restate its consolidated financial statements as of and for the quarters ended March 31, 2023 and June 30, 2023.
Nasdaq indicated that the Company must: (i) no later than January 22, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before May 20, 2024, file the delinquent Form10-Q.
The Company intends to file the delinquent Form 10-Q as soon as practicable.

Arvinas Announces Oversubscribed $350 Million Private Placement

Retrieved on:

Monday, November 27, 2023

Citadel, Goldman Sachs, Sale, LP, BofA Securities, Investment, ARVN, Prospectus, BB Biotech, Exercise, Security (finance)

The aggregate gross proceeds from the offering are expected to be approximately $350 million, before deducting placement agent fees and offering expenses.

Key Points:

The aggregate gross proceeds from the offering are expected to be approximately $350 million, before deducting placement agent fees and offering expenses.
The private placement is expected to close on or about November 28, 2023, subject to the satisfaction of customary closing conditions.
BofA Securities, Inc. and Goldman Sachs & Co. LLC acted as joint lead placement agents to Arvinas in connection with the private placement.
Arvinas has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement no later than the 30th day after the closing of the private placement.

Gorilla Token: Revolutionizing the Crypto Landscape with Innovative Features

Retrieved on:

Tuesday, November 21, 2023

Ethereum, Marketing, Policy, Ecosystem, Gorilla, Collection, KYC, IDO, LP, Non-fungible token, NFT, Diving, Growth, Cryptocurrency

Gorilla Token introduces its IDO Launchpad, named Gorilla Pad, designed to revolutionize how token projects kick off their presales.

Key Points:

Gorilla Token introduces its IDO Launchpad, named Gorilla Pad, designed to revolutionize how token projects kick off their presales.
Gorilla Token's foray into cross-chain trading is marked by its Gorilla Swap feature, a gateway to seamless trading across different blockchains.
Diving into the NFT space, Gorilla Token introduces the "Mad Gorilla Unified Cryptonairs" collection, comprising 3,333 unique NFTs minted on the Ethereum blockchain.
The roadmap also highlights the development of the IDO launchpad and Gorilla Swap, along with a focus on NFTs, demonstrating Gorilla Token's ambition to expand its footprint in the crypto world.

KBRA Assigns a Rating to the Class A Notes Issued by White Rose CFO 2023 Holdings, LLC

Retrieved on:

Thursday, December 28, 2023

Professional Services, Finance, Thrivent, Partnership, Jules Kroll, Acquisition, Note, KBRA, LP, European, Transaction, Net asset value, Asset, Loan, ESG, Disclosure, Insurance, Policy, Security (finance)

KBRA assigns a rating to the Class A Notes issued by White Rose CFO 2023 Holdings, LLC.

Key Points:

KBRA assigns a rating to the Class A Notes issued by White Rose CFO 2023 Holdings, LLC.
The Notes are indirectly backed by limited partnership (LP) interests in five different White Rose Funds of Funds (the "White Rose Funds"), which in turn hold a diversified pool of interests in private funds.
In aggregate, the White Rose Funds hold LP interests in 70 unique seasoned funds managed by 58 unique general partners (GP).
The allocable portion of the White Rose Funds that support the repayment of the Notes has a Net Asset Value of approximately $800 million and unfunded capital commitments of approximately $127 million as of October 31, 2023.

ENVOY ALERT: Bragar Eagel & Squire, P.C. is Investigating Envoy Medical, Inc. on Behalf of Envoy Stockholders and Encourages Investors to Contact the Firm

Retrieved on:

Saturday, December 23, 2023

Class Action Lawsuit, Professional Services, Legal, Telephone, FPA, LP, Financial statement, COCH, News, Bank statement, P.C, Affect, Life insurance

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Envoy Medical, Inc. (“Envoy” or the “Company”) (NASDAQ: COCH) on behalf of Envoy stockholders.

Key Points:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Envoy Medical, Inc. (“Envoy” or the “Company”) (NASDAQ: COCH) on behalf of Envoy stockholders.
Our investigation concerns whether Envoy has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On December 19, 2023, Envoy disclosed in a filing with the U.S. Securities and Exchange Commission that “[o]n December 14, 2023, the audit committee (the ‘Audit Committee’) of the board of directors of Envoy .

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation – COCH

Retrieved on:

Friday, December 22, 2023

Class Action Lawsuit, Professional Services, Legal, Titan, FPA, LP, COCH, News, Bank statement, Advertising

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21369 or call Phillip Kim, Esq.

Key Points:

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21369 or call Phillip Kim, Esq.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Thermo Fisher Scientific’s PPD Clinical Research Business Selected by BARDA to Support Phase II Platform Clinical Trial to Treat Acute Respiratory Distress Syndrome (ARDS)

Retrieved on:

Thursday, December 21, 2023

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).

Key Points:

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).
BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
Under this contract, the PPD clinical research business will implement a large Phase II clinical trial over three years.
The PPD clinical research business will support the clinical trial with its deep capabilities and expertise in end-to-end platform clinical trials, seamless biomarker testing, and critical care, drug depot and laboratory services.